Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer: A Phase II, Single-Arm Clinical Study

This study aims to evaluate the major pathologic response (MPR) rate of neoadjuvant therapy with sintilimab (PD-1 inhibitor) + IBI310 (anti-CTLA-4 antibody) + chemotherapy, and to assess the efficacy of this treatment strategy in patients with PD-L1-negative stage II - IIIB (excluding N3) NSCLC (according to AJCC 9th) scheduled for surgery.

Study Overview

• Status: Recruiting
• Conditions: NSCLC Stage II; NSCLC Stage III
• Intervention / Treatment: Drug: sintilimab+IBI310+chemotherapy

Detailed Description

Eligible patients were investigator - determined surgical candidates with resectable stage II-IIIB NSCLC, negative PD-L1 expression, no evidence of distant metastasis , and no evidence of unresectable localized tumor extension.

This study plans to enroll 54 patients.Patients are scheduled to receive one preoperative dose of sintilimab plus IBI310 combined with chemotherapy and three doses of sintilimab combined with chemotherapy as neoadjuvant therapy. Surgery will be performed on patients deemed operable by the investigator at least 3 weeks after the last dose of study drug. Following surgery, the investigator will assess the patient's response. Postoperatively, patients may continue receiving standard adjuvant therapy with PD-1 inhibitor for one year.

• Study Type: Interventional
• Enrollment (Estimated): 54
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Chang Chen, MD; Phone Number: +86 21 65115006; Email: changchenc@hotmail.com

Study Locations

• China
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China
      • Recruiting
      • Shanghai Pulmonary Hospital
      • Contact: Chang Chen, MD; Phone Number: +86 21 65115006; Email: changchenc@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

INCLUSION CRITERIA

1. The patient shall sign the informed consent.
2. Age ≥ 18 years.
3. Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC).
4. No prior anticancer therapy, including (but not limited to) chemotherapy, immunotherapy or radiotherapy. Traditional Chinese medicine given for anticancer intent is permitted provided it was discontinued ≥ 2 weeks before first dose.
5. Investigator-assessed resectable Stage II-IIIB (N3 excluded) NSCLC per AJCC 9th.
6. Non-squamous NSCLC: no EGFR mutation, ALK rearrangement or any other driver mutation with an approved targeted agent. Squamous NSCLC: no known EGFR mutation, ALK rearrangement or other actionable driver mutation.
7. PD-L1 expression negative (22C3 or E1L3N).
8. ECOG performance status 0 or 1.

9. Adequate organ function within 7 days before first dose:

   • Haemoglobin ≥ 90 g/L (no transfusion within 28 days)
   • Absolute neutrophil count ≥ 1.5 × 10⁹/L
   • Platelet count ≥ 100 × 10⁹/L (no platelet transfusion or IL-11 within 14 days)
   • Creatinine clearance ≥ 60 mL/min (Cockcroft-Gault)
   • Total bilirubin ≤ 1.5 × ULN (≤ 2.5 × ULN in Gilbert's syndrome or hepatic metastases)
   • ALT and AST ≤ 3 × ULN
   • INR or aPTT ≤ 1.5 × ULN
   • FEV> 2L, FEV1> 1L, FEV1/FVC ≥ 70%, DLCO ≥ 70% predicted; or Investigator determination that pulmonary reserve is adequate for planned surgery.
10. Fertile female must have a negative serum pregnancy test within 7 days before first dose.
11. Fertile female and male patients with female partners of childbearing potential must use a highly effective contraceptive method (annual failure rate < 1 %) from 7 days before first dose until 24 weeks after the last dose.

EXCLUSION CRITERIA

1. Major thoracic or abdominal surgery within 28 days before first dose or incomplete recovery from previous surgery.
2. Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids >10 mg/day) or other immunosuppressive agents for ≥ 7 consecutive days within 14 days before first dose. Except for inhaled or topical corticosteroids, or corticosteroid therapy at physiological replacement doses for adrenal insufficiency; short- courses (<7 days) corticosteroid use is permitted for the prevention or treatment of non-autoimmune conditions;
3. Participants who received live vaccines (including live attenuated vaccines) within 28 days before first dose.
4. Current or prior interstitial pneumonia or pulmonary diseases requiring systemic glucocorticoids.
5. Presence of any active autoimmune disease or history of autoimmune disease. Except in the following cases: Type 1 diabetes, stable hypothyroidism under hormone replacement therapy, psoriasis or vitiligo not requiring systemic treatment.
6. Other malignancy within 5 years before first dose, except for tumors assessed by the investigator as cured.

7. Uncontrolled comorbidities, including:

   • Active hepatitis B (HBsAg positive and HBV DNA > 500 IU/mL or > 2000 copies/mL) or hepatitis C (HCV antibody and HCV RNA positive). Subjects with HBV DNA ≤ 500 IU/mL who agree to antiviral prophylaxis are eligible.
   • Known HIV infection or history of AIDS.
   • Active tuberculosis.
   • Active infection requiring systemic antibiotics for > 7 days within 28 days before first dose.
   • Clinically significant cardiovascular disease: cerebrovascular accident within 6 months, symptomatic heart failure (NYHA class II-IV), unstable angina or myocardial infarction within 6 months, risk of QTc prolongation or arrhythmia.
   • Urine protein qualitative≥ 2+, and 24-hour urine protein test > 1g
8. History of allogeneic haematopoietic stem-cell or solid-organ transplantation.
9. Hypersensitivity to antibody therapies (≥ grade 3 NCI-CTCAE v6.0), history of anaphylaxis, uncontrolled asthma, or significant drug allergies.
10. Pregnancy or lactation.
11. Other conditions that may affect the safety or compliance of drug therapy in this study include, but are not limited to, psychiatric disorders, uncontrolled large serosal cavity effusions, or moderate to large serosal cavity effusions requiring repeated drainage (recurring within 2 weeks after intervention), such as pleural effusion, pericardial effusion, or ascites cachexia.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: sintilimab+IBI310+chemotherapy; Neoadjuvant therapy phase: four planned doses of sintilimab 200 mg, intravenous infusion at weeks -12, -9, -6, and -3 (Q3W); one planned dose of IBI310 1 mg/kg intravenous infusion at week -12; four planned doses of chemotherapy at weeks -12, -9, -6, and -3 (Q3W).Non-squamous NSCLC: pemetrexed 500 mg/m² IV and carboplatin AUC 5 IV. Squamous NSCLC: nab paclitaxel 260 mg/m² IV and carboplatin AUC 5 IV.; Surgery phase: At least 3 weeks after the last dose of the study drug , participants deemed operable by the investigator will undergo surgery, and then can continue to receive standard adjuvant therapy for one year.

Drug: sintilimab+IBI310+chemotherapy; Neoadjuvant therapy phase: four planned doses of sintilimab 200 mg intravenous infusion at weeks -12, -9, -6, and -3 (Q3W); one planned dose of IBI310 1 mg/kg intravenous infusion at week -12; four planned doses of chemotherapy at weeks -12, -9, -6, and -3 (Q3W). Non-squamous NSCLC: pemetrexed 500 mg/m² IV over 30 min and carboplatin AUC 5 IV over 120 min or per institutional standard. Squamous NSCLC: nanoparticle albumin-bound paclitaxel 260 mg/m² IV over 30 min and carboplatin AUC 5 IV over 120 min or per institutional standard.; Surgery phase: At least 3 weeks after the last dose of the study drug , participants deemed operable by the investigator will undergo surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
MPR Rate	Defined as the proportion of patients who have achieved major pathologic response (with ≤10% viable tumor cells) in all patients after surgery.	about 5 months after enrollment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)	Incidence and severity of adverse events (according to CTCAE v6.0 criteria), severity and its relationship to the experimental treatment; any abnormal laboratory test results, vital signs and physical examination results, etc.	From the subject's written consent to participate in the study through 30 days after the final administration of the drug
pCR Rate	Defined as the proportion of all patients who completed treatment and had no invasive viable tumor in both the primary tumor and the sampled lymph nodes after surgery.	about 5 months after enrollment
Overall Response Rate (ORR)	The proportion of patients who have had a complete response (CR) or partial response (PR) (according to RECIST1.1) after the neoadjuvant therapy.	12 weeks
Event Free Survival (EFS)	The time from enrollment to first occurrence of progression, disease recurrence (including local and distant recurrence), or death from any cause is assessed according to RECIST v1.1.	up to 5 years
Overall Survival (OS)	Defined as the time from enrollment to the participant's death from any cause.	up to 5 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor microenvironment and biomakers exploration	Surgical samples after neoadjuvant therapy and whole blood samples from patients prior to treatment, after two treatment cycles, and before surgery will be collected for single-cell RNA sequencing and proteomic analysis to analyze the tumor microenvironment and to explore the correlation between biomarkers and efficacy and safety.	up to 5 years

Collaborators and Investigators

• Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Study record dates

Study Major Dates

• Study Start (Actual): January 10, 2026
• Primary Completion (Estimated): June 10, 2028
• Study Completion (Estimated): January 10, 2030

Study Registration Dates

• First Submitted: January 23, 2026
• First Submitted That Met QC Criteria: February 6, 2026
• First Posted (Actual): February 13, 2026

Study Record Updates

• Last Update Posted (Actual): February 13, 2026
• Last Update Submitted That Met QC Criteria: February 6, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: neoadjuvant; NSCLC; CTLA-4
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Insulin-Dependent, 12
• Other Study ID Numbers: STAR-018

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No